REPLIGEN CORP Inventory, Raw Materials, Net of Reserves
REPLIGEN CORP (RGEN) had Inventory, Raw Materials, Net of Reserves of $97.33 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Inventory, Net, Items Net of Reserve Alternative
us-gaap:InventoryRawMaterialsNetOfReserves · last filed 2026-07-29
- 2026-06-30: Inventory, Raw Materials, Net of Reserves $97.33M.
- 2026-03-31: Inventory, Raw Materials, Net of Reserves $97.10M.
- 2025-12-31: Inventory, Raw Materials, Net of Reserves $94.63M.
- 2025-09-30: Inventory, Raw Materials, Net of Reserves $79.31M.
| Period end | Inventory, Raw Materials, Net of Reserves | Inventory, Raw Materials, Net of Reserves as first filed |
|---|---|---|
| 2026-06-30 | $97.33M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $97.10M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $94.63M 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $79.31M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $78.16M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $83.25M 10-Q · filed 2025-04-29 | |
| 2024-12-31 | $82.21M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $106.84M 10-Q · filed 2024-11-18 | |
| 2024-06-30 | $111.49M 10-Q/A · filed 2024-11-18 | |
| 2024-03-31 | $118.76M 10-Q/A · filed 2024-11-18 | |
| 2023-12-31 | $123.60M 10-K · filed 2025-03-14 | |
| 2023-09-30 | $128.89M 10-Q/A · filed 2024-11-18 | |
| 2023-06-30 | $148.00M 10-Q/A · filed 2024-11-18 | |
| 2023-03-31 | $150.40M 10-Q/A · filed 2024-11-18 | |
| 2022-12-31 | $149.44M 10-Q/A · filed 2024-11-18 | |
| 2022-09-30 | $146.80M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $141.67M 10-Q · filed 2022-08-02 | |
| 2022-03-31 | $137.29M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $123.32M 10-K · filed 2023-02-22 | |
| 2021-09-30 | $105.16M 10-Q · filed 2021-10-28 | |
| 2021-06-30 | $87.44M 10-Q · filed 2021-07-27 | |
| 2021-03-31 | $66.89M 10-Q · filed 2021-05-04 | |
| 2020-12-31 | $48.75M 10-K · filed 2022-02-17 | |
| 2020-09-30 | $42.20M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $40.20M 10-Q · filed 2020-07-30 | |
| 2020-03-31 | $34.75M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $29.33M 10-K · filed 2021-02-24 | |
| 2019-09-30 | $29.20M 10-Q · filed 2019-10-31 | |
| 2019-06-30 | $32.37M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $26.90M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $24.94M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $24.35M 10-Q · filed 2018-11-01 | |
| 2018-06-30 | $23.95M 10-Q · filed 2018-08-02 | |
| 2018-03-31 | $21.83M 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $22.35M 10-K · filed 2019-03-01 | |
| 2017-09-30 | $22.23M 10-Q · filed 2017-11-09 | |
| 2017-06-30 | $16.54M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $15.42M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $14.95M 10-K · filed 2018-02-22 | |
| 2016-09-30 | $15.57M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $14.89M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $12.58M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $10.67M 10-K · filed 2017-02-23 | |
| 2015-09-30 | $8.79M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $8.00M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $5.71M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $5.37M 10-K · filed 2016-02-25 | $5.37M 10-K · filed 2015-03-17 |
| 2014-09-30 | $5.72M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $5.18M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $4.22M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $4.56M 10-K · filed 2015-03-17 | |
| 2013-09-30 | $4.36M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $4.34M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $4.66M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $4.06M 10-K · filed 2014-03-14 | |
| 2012-09-30 | $3.21M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $3.00M 10-Q · filed 2012-08-09 | |
| 2011-12-31 | $3.56M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |